ArticleWorld journal of gastrointestinal oncology2025
Associations between serum biomarkers and gut microbial imbalance in predicting chemotherapy response in colorectal cancer: A retrospective analysis.
Article in World journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) remains one of the leading causes of cancer-related morbidity and mortality worldwide. Growing evidence suggests that gut microbial dysbiosis plays a crucial role in tumorigenesis and can influence therapeutic responses.
aimTo explore the associations between serum S100A12 and soluble CD14 (sCD14) levels and gut microbiota alterations in patients with CRC, and to assess the predictive utility of these biomarkers in forecasting chemotherapy response.
methodsA retrospective analysis was conducted on 104 patients diagnosed with advanced CRC (CRC group) and 104 age-matched and sex-matched healthy controls. Serum concentrations of S100A12 and sCD14 were measured using enzyme-linked immunosorbent assay. Fecal samples collected before chemotherapy were subjected to 16S rRNA sequencing to profile gut microbial composition. Pearson correlation analysis was used to evaluate the relationship between biomarker levels and microbial abundance. Receiver operating characteristic (ROC) curves were used to assess the predictive performance of S100A12 and sCD14 for chemotherapy response.
resultsCRC patients exhibited significantly higher serum levels of S100A12 and sCD14 compared to healthy individuals (
conclusionSerum S100A12 and sCD14 levels are closely associated with gut microbiota imbalance and chemotherapy response in CRC patients. These markers may serve as promising predictive indicators for treatment efficacy and offer potential value in individualized treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.